KESTRA MEDICAL TECHNOLOGIES, LTD.

For the period ended Apr 30, 2026. Filed Jul 14, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Jul 14, 2026

KMTS$29.55-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Year Ended April 30,
	2026	2025
Revenue	$95,126	$59,815
Cost of revenue	46,263	35,605
Gross profit	48,863	24,210
Operating expenses:
Research and development	19,484	15,652
Selling, general and administrative	164,120	114,936
Total operating expenses	183,604	130,588
Loss from operations	(134,741)	(106,378)
Other expense (income):
Interest expense	7,546	7,734
Interest income	(8,351)	(3,199)
Other expense (income)	(2,618)	2,766
Net loss before provision for income taxes	(131,318)	(113,679)
Provision for income taxes	294	135
Net loss	(131,612)	(113,814)
Less: Undeclared preferred stock dividends	—	12,321
Net loss attributable to common shareholders, basic and diluted	$(131,612)	$(126,135)
Net loss per share attributable to common shareholders, basic and diluted	$(2.43)	$(5.13)
Weighted-average shares of common shares outstanding, basic and diluted1	54,184,698	24,583,745
Other comprehensive loss:
Net loss	$(131,612)	$(113,814)
Unrealized loss on marketable securities	(218)	—
Comprehensive loss	$(131,830)	$(113,814)

1 Weighted-average shares of common shares outstanding, basic and diluted, has been adjusted on a retrospective basis. Refer to Note 16 “Net Loss Per Share Attributable to Common Shareholders” for additional disclosure.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.